Clinical Research Directory

Inclusion Criteria: 1. Pathological diagnosis of endometrial adenocarcinoma G1-2 of the endometrium 2. If the pathology is endometrial cancer, MRI or ultrasound confirms that the lesion is limited to the endometrium or invading the muscle\<1/2, that is, FIGO (2009) stage IA 3. Age ≤ 45 years old 4. Require those who wish to retain their reproductive function to sign informed consent 5. No serious internal medicine complications (severe liver and kidney dysfunction) 6. No contraindications for progesterone treatment or pregnancy 7. Has not experienced hypotension more than three times in the past six months and can be regularly monitored for blood pressure 8. Imaging shows no evidence of distant metastasis 9. A. Initial treatment patients: have not used any protective treatment drugs (progestogens, GNRH-a); B. One course of treatment (12 weeks) with incomplete remission of the lesion (partial remission, persistent or progressive lesion); C. Two courses of treatment (24 weeks) with incomplete remission (partial remission, persistent or progressive lesions); Exclusion Criteria: 1. Tumor invasion of muscle layer\>1/2, FIGO (2009) stage IB or above 2. Tumor differentiation into G3 or non endometrioid adenocarcinoma 3. Merge malignant tumors from other parts 4. Individuals with contraindications to conservative treatment or medication use 5. Patients known to have experienced hypotension 6. Patients who have taken other types of antihypertensive drugs regularly in the past